Li Chen

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

Alexa B. Kimball, Gregor B. E. Jemec, Afsáneh Alavi et al. · The Lancet · 2023 · 270 citations

Inflammation, Double-blind Phase 3, Week 16 +5

Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Dalong Zhu, Jianhua Ma, Jiao’e Zeng et al. · Nature Medicine · 2022 · 87 citations · Full text

Metabolic Syndrome, Diabetes Management, Placebo-controlled Phase 3 +8

Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Wenying Yang, Dalong Zhu, Shenglian Gan et al. · Nature Medicine · 2022 · 73 citations · Full text

Metabolic Syndrome, Adverse Events, Diabetes Management +10

Dorzagliatin (HMS5552), a novel dual‐acting glucokinase activator, improves glycaemic control and pancreatic β‐cell function in patients with type 2 diabetes: A 28‐day treatment study using biomarker‐guided patient selection

Xiaoxue Zhu, Dalong Zhu, Yalin Li et al. · Diabetes Obesity and Metabolism · 2018 · 59 citations

Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes

Elaine Chow, Ke Wang, Cadmon K.P. Lim et al. · Diabetes · 2022 · 44 citations · Full text

Insulin Signaling, Metabolic Syndrome, Molecular Pharmacology +21